MedTrace Logo

Description of the Population With Genitourinary Tumors and COVID-19

NCT04578132 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 410

Last updated 2025-04-01

Study results available
· View outcomes & findings →

Summary

The identification of patients with genitourinary tumors who suffer from the infection by the Serious Acute Respiratory Syndrome Corona-Virus 2 (SARS-CoV-2) virus can represent multiple benefits both for themselves and for health professionals and the health system itself. We would be able to know more precisely the clinical evolution of these type of patient, to know their prognosis and being capable to select the most appropriate treatment modality for future pandemics.

SOGUG-COVID is an observational prospective-retrospective trial purely epidemiological, that aims to describe the population with genitourinary tumors (urothelial cancer, prostate cancer, testicular cancer and kidney cancer) infected by COrona VIrus Disease 19 (COVID-19) treated in Spanish hospitals, learn about the clinical presentation, therapeutic evolution and prognosis of said intercurrent infectious process, as well as its possible relationship with different clinical and therapeutic factors.

Conditions

  • Covid19
  • Genito Urinary Cancer

Sponsors & Collaborators

  • Spanish Oncology Genito-Urinary Group

    lead OTHER

Principal Investigators

  • Miguel Ángel Climent, M.D., Ph.D. · Instituto Valenciano de Oncología

  • Javier Puente, M.D., Ph.D. · Hospital Clínico San Carlos de Madrid

  • Aránzazu González del Alba, M.D., Ph.D. · Hospital Universitario Puerta de Hierro-Majadahonda

  • Sergio Vázquez Estevez, M.D., Ph.D. · Hospital Universitario Lucus Augusti

  • Natalia Vidal, M.D., Ph.D. · Hospital Clínico San Carlos de Madrid

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-18
Primary Completion
2022-11-23
Completion
2022-11-23

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04578132 on ClinicalTrials.gov